This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area

Key Points
CRISPR Therapeutics has a pair of candidates that could transform how we address certain risk factors for cardiovascular conditions.
They aren't the only promising candidates in the pipeline, either.
However, CRISPR Therapeutics carries above-average risk.
- 10 stocks we like better than CRISPR Therapeutics ›
CRISPR Therapeutics (NASDAQ: CRSP) has significantly lagged broader equities over the past five years. There are several reasons for that. Challenging economic conditions have led investors to rotate their money out of somewhat speculative investments, and it also doesn't help that the biotech's only approved medicine has, so far, generated little revenue. However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help redefine an entire therapeutic area. Let's dig in.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Shooting for the stars
CRISPR Therapeutics has a fair number of pipeline candidates for a biotech worth a bit under $5 billion. Using its gene-editing platform, the company is targeting various areas with high unmet needs. Some of its most promising products in development are aiming to address risk factors for cardiovascular disease. Consider, for instance, CTX310, being developed for certain patients with high levels of LDL cholesterol and triglycerides (TGs) due to various conditions, including some genetic disorders.
CTX310 targets the ANGPTL3 gene (inhibiting ANGPTL3 protein function), which plays an important role in regulating LDL and TGs; both, at high levels, can cause coronary artery disease. Why could CTX310 redefine this therapeutic area? First, CRISPR Therapeutics is focusing on high-risk patients for whom current treatment options are somewhat limited.
Second, whereas patients typically take existing therapies to lower LDL and TGs over long periods, CTX310 could be a one-and-done gene-editing medicine. CRISPR Therapeutics estimates that 40 million people in the U.S. have high TG and LDL levels.
The company won't target all of them with CTX310, but even an addressable population that comprises a tiny portion of this market, like 0.1% (or 40,000 people), would be fairly large, given that the therapy would fill a high unmet need for these patients.
CRISPR Therapeutics' CTX320 is similarly looking to lower lipoprotein(a) -- a risk factor for major cardiovascular events -- in certain patients. It could also be a one-time cure for eligible individuals. These two candidates, if approved, would be important breakthroughs. Further, CRISPR Therapeutics has other exciting pipeline programs, including at least one that could be a functional cure for Type 1 diabetes -- that too would be a significant clinical success.
With all that said, it's important to highlight that there are significant risks here. CRISPR Therapeutics generates little revenue and is unprofitable. Although it has a promising pipeline, clinical or regulatory setbacks will sink its stock price. Here's the bottom line: CRISPR Therapeutics is a promising mid-cap biotech stock that is well-suited for investors comfortable with heightened risk and volatility. Risk-averse investors, on the other hand, will want to stay away.
Should you buy stock in CRISPR Therapeutics right now?
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $533,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,089,028!*
Now, it’s worth noting Stock Advisor’s total average return is 930% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 8, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.